» Articles » PMID: 29971255

Microenvironment and Tumor Cells: Two Targets for New Molecular Therapies of Hepatocellular Carcinoma

Overview
Specialty Gastroenterology
Date 2018 Jul 5
PMID 29971255
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma (HCC), is one of the most frequent human cancer and is characterized by a high mortality rate. The aggressiveness appears strictly related to the liver pathological background on which cancer develops. Inflammation and the consequent fibro/cirrhosis, derived from chronic injuries of several origins (viral, toxic and metabolic) and observable in almost all oncological patients, represents the most powerful risk factor for HCC and, at the same time, an important obstacle to the efficacy of systemic therapy. Multiple microenvironmental cues, indeed, play a pivotal role in the pathogenesis, evolution and recurrence of HCC as well as in the resistance to standard therapies observed in most of patients. The identification of altered pathways in cancer cells and of microenvironmental changes, strictly connected in pathogenic feedback loop, may permit to plan new therapeutic approaches targeting tumor cells and their permissive microenvironment, simultaneously.

Citing Articles

Achieving tolerance modifies cancer susceptibility profiles in liver transplant recipients.

Bhat M, Pasini E, Patel P, Yu J, Baciu C, Kurian S Cancer Med. 2022; 12(4):5150-5157.

PMID: 36205189 PMC: 9972022. DOI: 10.1002/cam4.5271.


The tumor microenvironment of hepatocellular carcinoma and its targeting strategy by CAR-T cell immunotherapy.

Guizhen Z, Guanchang J, Liwen L, Huifen W, Zhigang R, Ranran S Front Endocrinol (Lausanne). 2022; 13:918869.

PMID: 36093115 PMC: 9452721. DOI: 10.3389/fendo.2022.918869.


Hepatocellular carcinoma chemoprevention by targeting the angiotensin-converting enzyme and EGFR transactivation.

Crouchet E, Li S, Sojoodi M, Bandiera S, Fujiwara N, El Saghire H JCI Insight. 2022; 7(13).

PMID: 35801591 PMC: 9310532. DOI: 10.1172/jci.insight.159254.


Exosome-Associated circRNAs as Key Regulators of EMT in Cancer.

Amicone L, Marchetti A, Cicchini C Cells. 2022; 11(10).

PMID: 35626752 PMC: 9140110. DOI: 10.3390/cells11101716.


The Bright and the Dark Side of TGF-β Signaling in Hepatocellular Carcinoma: Mechanisms, Dysregulation, and Therapeutic Implications.

Gungor M, Uysal M, Senturk S Cancers (Basel). 2022; 14(4).

PMID: 35205692 PMC: 8870127. DOI: 10.3390/cancers14040940.


References
1.
Parviz F, Matullo C, Garrison W, Savatski L, Adamson J, Ning G . Hepatocyte nuclear factor 4alpha controls the development of a hepatic epithelium and liver morphogenesis. Nat Genet. 2003; 34(3):292-6. DOI: 10.1038/ng1175. View

2.
Belghiti J, Fuks D . Liver resection and transplantation in hepatocellular carcinoma. Liver Cancer. 2013; 1(2):71-82. PMC: 3747544. DOI: 10.1159/000342403. View

3.
Lee D, Chung Y, Kim J, Lee Y, Lee D, Jang M . Transforming growth factor beta 1 overexpression is closely related to invasiveness of hepatocellular carcinoma. Oncology. 2012; 82(1):11-8. DOI: 10.1159/000335605. View

4.
Wilhelm S, Carter C, Tang L, Wilkie D, McNabola A, Rong H . BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004; 64(19):7099-109. DOI: 10.1158/0008-5472.CAN-04-1443. View

5.
Wang C, Sun H, Gao X, Ren N, Sheng Y, Wang Z . Interleukin-6 enhances cancer stemness and promotes metastasis of hepatocellular carcinoma via up-regulating osteopontin expression. Am J Cancer Res. 2016; 6(9):1873-1889. PMC: 5043100. View